Carmila Launches a Tender Offer on Its Bonds Maturing in September 2023 and September 2024, and Announces Its Plan to Issue a New Bond
Carmila (Paris:CARM) is to launch a tender offer for an amount of €300 million – which may be revised at Carmila’s discretion – on bonds maturing on 18 September 2023 and representing a residual amount of €600 million, and on bonds maturing on 16 September 2024 and representing a residual amount of €587.8 million. The Group is also announcing its plan to issue a new bond for €300 million upon expiry of said tender offer.
These operations will enable Carmila to (i) optimise its bond maturities by redeeming its shorter-term bond debt and issuing longer-term bonds in its place, (ii) limit the surplus cash generated by the operation, and (iii) manage its borrowing costs.
The offer is subject to the terms and conditions set out in the Tender Offer Memorandum dated 16 November 2020.
The new bond issue will be launched if Carmila considers that enough bondholders participate in the tender offer, and provided that market conditions are satisfactory. Priority allocation rights to the new issue may apply for bondholders tendering their bonds to the offer, at Carmila’s sole and total discretion.
The tender offer will run from 16 November 2020 to 4:00 p.m. (Paris time) on 20 November 2020.
The results of the offer will be announced at the latest on the date of the new bond issue.
The new bond issue would take place as from 23 November 2020.
Carmila is holding a global investor call to discuss this operation at 2.30 p.m. (Paris time) on 17 November 2020.
17 February 2021 (after trading): 2020 Annual Results
18 February 2021 (9:00 a.m. Paris time): Investor and Analyst Meeting
22 April 2021 (after trading): First-quarter 2021 Financial Information
28 July 2021 (after trading): 2021 Half-year Results
29 July 2021 (2:30 p.m. Paris time): Investor and Analyst Meeting
As the third largest listed owner of commercial property in continental Europe, Carmila was founded by Carrefour and large institutional investors in order to transform and enhance the value of shopping centres adjoining Carrefour hypermarkets in France, Spain and Italy. At 30 June 2020, its portfolio was valued at €6.2 billion, comprising 215 shopping centres, all leaders in their catchment areas. Driven by an ambition to simplify and enhance the daily lives of retailers and customers across the regions, the local touch is at the heart of everything Carmila does. Carmila’s teams have a deeply-anchored retail culture, comprising experts in all aspects of retail attractiveness: operations, shopping centre management, leasing, local digital marketing, business set-ups and CSR.
Carmila is listed on Euronext-Paris Compartment A under the symbol CARM. It benefits from the tax regime for French real estate investment trusts (“SIIC”).
Carmila became part of the FTSE EPRA/NAREIT Global Real Estate (EMEA Region) indices on 18 September 2017.
Carmila became part of the Euronext CAC Small, CAC Mid & Small and CAC All-tradable indices on 24 September 2018.
Some of the statements contained in this document are not historical facts but rather statements of future expectations, estimates and other forward-looking statements based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or events to differ materially from those expressed or implied in such statements. Please refer to the most recent Universal Registration Document filed in French by Carmila with the Autorité des marchés financiers for additional information in relation to such factors, risks and uncertainties. Carmila has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Carmila accepts no liability for any consequences arising from the use of any of the above statements.
INVESTOR AND ANALYST
Florence Lonis – General Secretary
+33 6 82 80 15 64
Morgan Lavielle - Corporate Communications Director
+33 6 87 77 48 80
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lineage Logistics Enters the Polish Cold Storage Market With the Acquisition of Pago Sp. z o.o.1.12.2020 18:04:00 CET | Press release
Lineage Logistics Holdings, LLC (“Lineage” or the “Company”), the world’s largest and most innovative temperature-controlled industrial REIT and logistics solutions provider, today announced it has acquired Pago Sp. z o.o. (“Pago”), a leading warehousing, distribution and transport logistics provider in Poland from its current ownership, including Tönnies International Holding GmbH (“Tönnies”). The strategic acquisition marks the Company’s entrance into the Polish market and adds six exceptional assets to Lineage’s global network of temperature-controlled facilities. Lineage was founded and continues to be managed by Bay Grove Capital, LLC (“Bay Grove”), a principal investment firm dedicated to partnering with strong management teams to build long-term platform investments. Financial terms of the transactions were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005951/en/ The acquisition of Pago Sp. z o.o
Sumitomo SHI FW fluidized bed technology – upscaling thermochemical energy storage to a commercial level1.12.2020 17:47:00 CET | Press release
One of the largest obstacles in using renewable energy efficiently is the possibility to store energy on a large scale. SaltX Technology AB has partnered with Sumitomo SHI FW (SFW) to solve this in terms of heat energy. "The storage solution is like a "salt battery". It is based on a basic chemical process with a very common material, calcium oxide produced from limestone, with enhanced properties by our nanocoating process", explains Carl-Johan Linér, CEO of SaltX. Simplified, when calcium oxide reacts with water, it turns into calcium hydroxide and releases heat. Respectively, when calcium hydroxide is dried, it absorbs heat. SFW has designed a fluidized bed pilot reactor, which serves as the point of discharge, where the salt releases the heat. The new 100 kW reactor in SaltX's new testing installation in Sweden, near Stockholm, combines the performance of SaltX's patented nanocoated salt with SFW's fluidized bed technology. "SFW's technology has huge potential to take the salt batt
PierianDx Announces Expanded Partnership with Illumina to Support Cancer Genomic Reporting in Global Markets1.12.2020 17:00:00 CET | Press release
PierianDx, the leading clinical genomics informatics company, today announced an expanded partnership with Illumina to enable PierianDx genomic reporting solutions for use with AmpliSeq™ for Illumina® Focus Panel, AmpliSeq™ for Illumina® Myeloid Panel and the TruSight™ Hereditary Cancer Panel. Adding these panels expands the existing relationship between Illumina and PierianDx, which currently covers use of the PierianDx platform to support genomic reporting in key global markets for the TruSight Oncology 500 portfolio. Performing a comprehensive NGS test and delivering an accompanying genomic report were once only accomplished via a send-out test to a commercial lab. However, in performing tests as send-outs, healthcare organizations relinquish control over samples, turnaround time, and quality. The PierianDx platform enables healthcare organizations to accelerate their precision medicine programs by empowering them to create accurate, timely, and comprehensive clinical genomic report
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 20201.12.2020 16:01:00 CET | Press release
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients. Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity
Andersen Global Adds Collaborating Firm in Azerbaijan1.12.2020 15:30:00 CET | Press release
Andersen Global expands into Azerbaijan by way of a Collaboration Agreement with independent Baku-based law firm MGB Law Offices, adding coverage and positioning the organization for further expansion between Europe and Asia. Founded in 1995, MGB Law Offices, which has ten lawyers, has been recognized by IFLR1000, Legal500 and Chambers and Partners as the leading law firm in Azerbaijan. Led by Managing Partner Ismail Askerov, the full-service firm offers solutions in various industries such as oil and gas, aviation, banking and finance, insolvency and restructuring, tax, privatization law and foreign investment. The firm’s client base includes blue-chip multinationals, international financial institutions, insurance companies, airlines, telecom companies and other business entities. “We are proud of our ability to consistently deliver best-in-class services, and our comprehensive solutions position us to be one of the most reputable law firms in the market by allowing us to meet the di
Alira Health Achieves AWS Select Consulting Partner Status1.12.2020 15:00:00 CET | Press release
Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, announced it has recently earned Amazon Web Services (AWS) Select Consulting Partner status. The firm’s newly formed Advanced Analytics practice will leverage AWS’s cloud computing capabilities to provide greater value to clients, providing fully compliant, made-to-measure digital solutions, powered by AWS, that securely enable the use of data generated by the healthcare community and clients’ own internal data. The solutions are provided to customers in the form of Software-as-a-Service (SaaS), seamlessly integrating into existing workflows and designed to support clients in prioritizing research and development (R&D) investments, identifying novel therapeutic areas suitable for corporate business development, and assessing business opportunities. “Technology has the power to solve complex problems and be a transformative tool across the healthcare and life sciences ecosystem,” said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom